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Abstract 
Background: Repeated exposure to Plasmodium falciparum is associated with perturbations in B cell sub‑set 
homeostasis, including expansion atypical memory B cells. However, B cell perturbations immediately following 
acute malaria infection have been poorly characterized, especially with regard to their relationship with immunity to 
malaria.
Methods: To better understand the kinetics of B cell sub‑sets following malaria, the proportions of six B cell sub‑sets 
were assessed at five time points following acute malaria in four to 5 years old children living in a high transmission 
region of Uganda. B cell sub‑set kinetics were compared with measures of clinical immunity to malaria—lower para‑
site density at the time of malaria diagnosis and recent asymptomatic parasitaemia.
Results: Atypical memory B cell and transitional B cell proportions increased following malaria. In contrast, plasma‑
blast proportions were highest at the time of malaria diagnosis and rapidly declined following treatment. Increased 
proportions of atypical memory B cells were associated with greater immunity to malaria, whereas increased propor‑
tions of transitional B cells were associated with evidence of less immunity to malaria.
Conclusions: These findings highlight the dynamic changes in multiple B cell sub‑sets following acute, uncompli‑
cated malaria, and how these sub‑sets are associated with developing immunity to malaria.
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Background
Malaria caused by Plasmodium falciparum continues to 
cause over a half million deaths each year, with children 
being disproportionately affected [1]. Children suffer 
the greatest morbidity and mortality from malaria since 
immunity to malaria takes years to develop, increas-
ing with age and exposure [2, 3]. One manifestation of 
acquired immunity to malaria is control of blood stage 
parasites, resulting in lower parasite densities and lack of 
febrile symptoms of disease [4–6]. Antibodies have been 
shown to be an important mediator of this blood stage 
immunity [7–10].
Effective B cell and antibody responses to Plasmodium 
infection generally develop only after years of repeated 
exposure, likely due to immune immaturity of the host 
and antigenic variation of parasites [8–12]. Another 
hypothesis for the slow development of immunity is that 
Plasmodium infection may interfere with B cell develop-
ment and maintenance of memory responses [13–17]. 
After initial maturation in the bone marrow, B cells pass 
through a series of developmental differentiation stages, 
many of which can be detected in the peripheral blood. 
Transitional B cells emerge from the bone marrow and 
mature into naïve B cells prior to antigen exposure. After 
antigen exposure, B cells in secondary lymphoid organs 
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differentiate into class-switched classical memory B cells 
(MBCs) non-class switched ‘innate-like’ MBCs and anti-
body-secreting plasmablasts/plasma cells [18]; these cells 
can be detected in blood as they migrate to other second-
ary lymphoid organs and tissues. Exposure to Plasmo-
dium alters the distribution of these B cell sub-sets, and 
has been associated with an expansion of ‘atypical’ MBCs 
in individuals living in malaria-endemic areas [13–15, 
19]. Atypical MBCs are class-switched but lack the clas-
sical MBC marker CD27, and unlike classical MBCs, do 
not appear to readily produce antibodies [13, 20, 21]. 
This functional difference has led to the hypothesis that 
atypical MBCs may be ‘exhausted’ and may interfere 
with development of effective immunity [13, 21]. On 
the other hand, higher circulating proportions of atypi-
cal MBCs and immunity to malaria are both associated 
with increasing age and P. falciparum exposure [13, 14, 
22–24]. Thus, the relationship between atypical MBCs 
and immunity to malaria remains unclear.
B cell sub-sets generated during malaria episodes 
may indicate which B cells are associated with develop-
ing immunity. Various studies have described multiple 
B cell sub-sets in people exposed to varying levels of 
malaria [11, 13, 14, 20–23, 25, 26], but the kinetics of 
B cell responses following malaria have not been well 
described in humans. One study tracked the kinetics 
transitional B cells following malaria and found that the 
relative proportion of these cells increased following 
malaria [19]. Studies of experimental infection of mice 
with Plasmodium chabaudi have found that newly dif-
ferentiated plasmablasts only circulate in the blood for 
a short time following primary or secondary infection 
while other sub-sets such as transitional, naïve B cells 
and MBCs fluctuate greatly but remain readily detect-
able in the peripheral blood [26]. These findings sug-
gest that there are likely to be dynamic changes in the 
composition of the B cell pool both during and follow-
ing acute malaria in humans, and that these changes may 
be reflected in the peripheral blood. Here, the kinetics of 
six distinct sub-sets of B cells were evaluated during and 
after treatment for symptomatic malaria, and sub-set 
proportions were evaluated for associations with meas-
ures of immunity to malaria.
Methods
Study cohort
Samples were obtained from participants between 4.6 
and 5.0 years of age enrolled in the Tororo Child Cohort 
(TCC) study in Tororo, Uganda, an area of intense 
malaria transmission (annual entomological inocula-
tion rate in the region estimated at 125 infectious bites 
per person year) [27]. Cohort details have been described 
elsewhere [28–30], but in brief, TCC children were 
enrolled at infancy (mean 2.7 months old) and followed 
to 5  years of age at a dedicated study clinic, providing 
all medical care. Febrile participants (>38  °C tympanic 
temperature or reported fever in the previous 24 h) were 
tested for P. falciparum parasites by thick blood smear. 
Febrile participants that had any detectable parasites by 
thick blood smear were diagnosed with symptomatic 
malaria and treated with an artemisinin-based combina-
tion therapy. Participants also had monthly blood smears 
to assess parasitaemia regardless of symptoms. For this 
study, 38 consecutive children were enrolled that pre-
sented with symptomatic malaria, with parasite densities 
greater than 2000 parasites/µl. Asymptomatic parasitae-
mia was defined by parasitaemia in afebrile participants 
occurring at least 14  days after and five days before a 
malaria episode.
Ethical permission
All study participants or their parents or guardians pro-
vided individual written informed consent. Approval was 
granted by the Uganda National Council of Science and 
Technology, the Makerere University Research and Eth-
ics Committee, the University of California, San Fran-
cisco Committee on Human Research,
Whole blood staining
A half ml of whole blood was collected through finger 
prick or phlebotomy. Whole blood was washed with 
PBS and then labelled for 30 min with antibodies against 
CD3 (clone UCHT1), CD14 (clone M5E2), CD19 (clone 
HIB19), CD10 (clone HI10a), CD38 (clone HIT2), CD27 
(clone O323), IgG (clone G18-145) (all BioLegend), and 
IgD (clone IA6-2) (BD Biosciences) (see Fig.  1 for gat-
ing strategy). Due to limitations in the number of stable 
fluorophores available in this assay, CD21 could not be 
included for analysis. However, previous studies have 
demonstrated that the majority of IgD- CD27-B cells 
are also CD21- and have similar expression profiles 
[20, 21, 31–36]. Whole blood was treated with Lyse/Fix 
buffer (BD Biosciences), to remove red blood cells and 
fix stained cells. Cells were then stored in PBS at −80 °C 
until stained and processed on an LSRII (Fig. 1). Prior to 
the initiation of this study, the stability of the fluorescent 
markers was verified with B cell sub-sets readily distin-
guishable up to six weeks after staining when stored at 
−80  °C. All samples were run on the LSRII within four 
weeks of staining. As inclusion criteria for this analysis, 
a minimum of 10,000 B cell events were collected, with 
each sub-set consisting of at least 200 events, from each 
time point. In order to limit variations or batch effects 
between LSRII cytometer uses, all flow cytometric data 
were collected using rainbow beads to equilibrate relative 
fluorescence.
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Statistical analysis
Changes in B cell sub-type proportions between day 0 
and other days were tested using the Wilcoxon signed 
rank test. Linear trends in proportion during follow-up 
were evaluated using generalized estimating equations 
[37] to account for repeated measures in the same indi-
vidual. To test the hypothesis that clinical immunity 
was associated with proportions of B cell sub-sets, the 
proportions during and following malaria with parasite 
density on day 0, with lower parasite density indicating 
greater immunity, and with the number of asymptomatic 
parasitaemia episodes in the prior 180  days, with more 
episodes indicating greater immunity. Parasite density 
was evaluated as a binary variable based on the median 
parasite density of 23,080 parasite/μl. Asymptomatic 
parasitaemia was evaluated as an ordinal variable of 0, 
1 or greater than 1 episode in the last 180  days, with a 
linear trend across the three categories evaluated. Asso-
ciations between the clinical metrics and B cell sub-types 
were evaluated using generalized estimating equations. 
To account for the potential confounding effects of prior 
exposure, a multivariate analysis including the incidence 
of malaria between 12 and 24  months of age was per-
formed, when the effect of acquired immunity was likely 
to be minimal as an estimate of prior exposure.
Results
Participant characteristics
For this study, 38 children between the ages of 4.6 and 
5.0 years were consecutively enrolled at the time of pres-
entation with symptomatic malaria and followed them 
for 28 days (Table 1). The age range was intentionally kept 
narrow since age may strongly affect immune responses 
and clinical immunity. All children lived in Tororo, a 
district of Uganda with intense perennial malaria trans-
mission, and were enrolled from a larger cohort study in 
which they had been followed since at least 10 months 
old [27, 29]. Table 1 shows the range of parasite densities 
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Fig. 1 Representative flow cytometry dot plot and gating hierarchy used to define B cell sub‑types using cell markers CD3/14, CD19, CD10, CD38, 
CD27, and IgD. Using these markers, six CD19+B cell sub‑sets are defined as: transitional (CD10+ CD27− IgD+), naïve (CD10− CD27− IgD+), innate‑
like MBCs (CD10− CD27+ IgD+), classical MBCs (CD10− CD27+ IgD−), atypical MBCs (CD10− CD27− IgD−), and plasmablasts/plasma cells (CD10− 
CD27hi CD38hi IgD−)
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at baseline, the number of episodes of symptomatic 
malaria and asymptomatic parasitaemia in the preceding 
180 days, and the proportion of participants who went on 
to have another bout of clinical malaria during the 28-day 
active surveillance period following treatment.
Atypical MBCs and transitional B cell proportions 
increased, whereas plasma cell and naïve B cell 
proportions decreased, following malaria
In order to characterize the kinetics of B cell sub-
sets following acute malaria, 6 B cell sub-sets were 
characterized from whole peripheral blood col-
lected at the time of malaria diagnosis (day 0), and 
on days 3, 7, 14, and 28 following treatment. Flow 
cytometry was used to measure the relative pro-
portions of: transitional B cells (CD19+CD10+), 
naïve B cells (CD19+CD10−IgD+CD27−), innate-
like MBCs (CD19+CD10−IgD+CD27+), classical 
MBCs (CD19+CD10−IgD−CD27+), atypical MBCs 
(CD19+CD10−IgD−CD27−), and plasmablasts/plasma 
cells (CD19+CD10−IgD−CD27hiCD38hi) (Fig.  1). The 
proportions of atypical MBCs and transitional B cells 
both increased in the 28 days following malaria (Fig. 2). 
Atypical MBC proportions increased from a mean of 
11.8 to 17.3 %, day 0 to day 28 (p < 0.001 for trend). In 
order to distinguish whether this trend represented an 
increase in atypical MBC proportions following malaria 
versus a transient decrease at the time of malaria, the 
proportions of atypical MBCs in participants that had a 
second malaria episode during the 28-day study obser-
vation period were evaluated. In participants that had a 
second malaria episode during the 28-day study observa-
tion period, the proportions of atypical MBCs increased 
further following the second malaria episode, from 11.5 
to 16.0 % (p = 0.04) (Fig. 3a), providing evidence against 
a transient decrease at the time of malaria. Transitional 
B cell proportions also increased following malaria, from 
a mean of 7.7 % on day 0 to 10.0 % on day 28 (p < 0.001 
for trend), however no additional increase in transitional 
B cells was observed in participants that had a second 
malaria episode during the 28-day study observation 
period.
In contrast, proportions of plasmablasts/plasma (PC) 
cells and naïve B cells decreased following malaria. Mean 
PC proportion was highest at 6.1  % on day 0 and then 
rapidly declined to 3.3  % by day 7 (p =  0.002). Partici-
pants with a second malaria episode during the 28-day 
study had increased PC proportions following second 
episode diagnosis (Fig. 3b), and this increase in PC pro-
portion was significantly higher in participants with 
a second malaria episode compared to the rest of the 
cohort. This suggests that plasmablasts, known to only 
circulate briefly in the peripheral blood, can be readily 
detected in significant numbers in the peripheral blood at 
the time of symptomatic malaria. Naïve B cell proportion 
decreases were moderate, from 57 to 51 % from day 0 to 
day 28 (p = 0.016). Classical memory B cell proportions 
had a transient drop on days 3 and 7 only, but otherwise 
remained unchanged throughout observation. No sig-
nificant fluctuations in innate-like MBC proportions was 
detected over the 28-day study.
Atypical memory B cell proportions were higher 
among children with evidence of immunity to malaria
Higher proportions of atypical MBCs and immunity to 
malaria are both positively associated with age and P. fal-
ciparum exposure. Therefore, this study sought to test 
if proportions of atypical MBCs were associated with 
measures of developing immunity to malaria. None of 
the participants included in this study were fully immune 
to symptomatic malaria, since malaria was the primary 
inclusion criteria for enrollment, however a range of clini-
cal immunity was noted in these children sharing a simi-
lar age range. Acquired immunity to malaria manifests as 
better control of blood stage parasites, resulting in lower 
parasite density and a decreased probability of infection 
developing into symptomatic malaria [2, 3, 38]. Therefore, 
participants were grouped based on parasite density at the 
time of malaria (Fig. 4a) and documented asymptomatic 
parasitaemia in the prior 180 days (Fig. 4b). A history of 
asymptomatic parasitaemia was associated with lower 
parasite density at presentation with malaria, as would be 
expected if both were indications of clinical immunity.
When participants were grouped based on median par-
asite densities (23,080 parasites/µl) at the time of malaria, 
participants with lower parasite density had higher pro-
portions of atypical MBCs during the 28 days following 
malaria (Table  2). A similar association was observed 
between the geometric mean parasite density over the 
previous 180  days and the proportion of atypical MBC 
over the 28 days following malaria (p = 0.02), indicating 
Table 1 Characteristics of study participants
a Median
b Recurrent malaria as defined symptomatic malaria in the 28 days following 
enrolment
Participants’ characteristic (n = 38) Mean Range
Age (years) 4.8 4.6–5.0
Parasite density on day 0 (parasites/µl) 23,080a 2000–180,000
Asymptomatic parasitaemia episodes in the 
prior 180 days
0.5 0–5
Symptomatic malaria episodes in the prior 
180 days
3.8 1–8
Proportion of participants with recurrent 
malariab
10/38
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some temporal stability in the clinical phenotype of con-
trol of blood-stage parasites. Participants with more doc-
umented episodes of asymptomatic parasitaemia within 
the prior 180  days were also found to have higher pro-
portions of atypical MBCs following malaria. These asso-
ciations remained significant and largely unchanged after 
adjusting the analysis for varied P. falciparum exposure. 
Further, these associations were consistent throughout 
the 28  days following malaria (Fig.  4c, d). Proportions 
were more strongly associated with day 0 parasite density 
than with asymptomatic parasitaemia, and in a multivari-
ate analysis including both of these correlated measures, 
only parasite density remained significant (p  <  0.001). 
Together, these findings indicate that measures of greater 
immunity to malaria were associated with increased pro-
portions of atypical MBCs in the peripheral blood follow-
ing malaria.
Transitional B cell proportions were lower among children 
with evidence of immunity to malaria
In contrast to atypical MBCs, transitional B cell propor-
tions were lower in participants that had parasite den-
sity less than the median at the time of malaria (Table 2), 
but no significant association with asymptomatic para-
sitaemia was found. The association with parasite den-
sity remained significant after adjusting the analysis for 
varied P. falciparum exposure. Further, this association 
was consistent throughout the 28 days following malaria 
(Fig.  4c). A similar association was found between the 
geometric mean parasite density over the previous 
180 days and the proportion of transitional B cells follow-
ing malaria. This finding indicates that participants with 
evidence of greater immunity to malaria tend to have 
lower proportions of transitional B cells in the peripheral 
blood following malaria.
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Fig. 2 B cell kinetics following acute malaria. Graphs show the mean proportion, with bars denoting 95 % confidence intervals, of each B cell sub‑
type. Asterisk, double asterisk and triple asterisk indicate a significant difference in proportion from day 0 as assessed by the Wilcoxon rank sum test 
(p < 0.05, 0.01 and 0.001, respectively). Day 0 n = 36, day 3 n = 36, day 7 n = 38, day 14 n = 36, and day 28 n = 36
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Associations between other B cell sub‑types and immunity 
to malaria
Proportions of circulating plasma cells/plasmablasts rap-
idly decreased following malaria (day 0), but were not 
significantly associated with measures of immunity to 
malaria. There were no significant associations between 
measures of immunity to malaria and the proportions of 
classical MBCs, innate-like MBCs or naïve B cells.
Discussion
This study investigated the kinetics of different B cell sub-
sets at the time of and following symptomatic malaria 
and then evaluated whether proportions of these sub-sets 
were associated with measures of immunity to malaria. 
The proportions of atypical MBCs and transitional B cells 
both increased during the 28 days following symptomatic 
malaria, whereas naïve B cell proportions declined slowly 
and circulating PCs proportions declined rapidly follow-
ing treatment of malaria, increasing again in participants 
who had a second episode of malaria. Notably, children 
with evidence of greater immunity to malaria had higher 
proportions of atypical MBCs and lower proportions of 
transitional B cells following malaria, and these associa-
tions remained stable over the 28 days following malaria. 
These findings suggest that children with higher propor-
tions of these cells during and following malaria have 
improved immune responses to P. falciparum infection.
People living in malaria-endemic regions have 
increased proportions of atypical MBCs, with these pro-
portions increasing with age and with cumulative Plas-
modium exposure [11, 13, 14]. Atypical MBCs have been 
characterized as having upregulated inhibitory pathways 
compared to classical MBCs [13, 20, 21]. Despite one 
report suggesting serum antibodies may be produced 
by atypical MBCs [22], other studies have reported that 
atypical MBCs have a poor capacity for differentiation 
and antibody production [13, 20, 21]. With no direct 
evidence for an alternative function for atypical MBCs, 
these cells have been hypothesized to represent a dys-
functional or ‘exhausted’ phenotype. However, atypical 
MBC proportion, like immunity to symptomatic malaria, 
is associated with age and transmission intensity [20, 24]. 
This study was not able to evaluate a causal relationship 
between atypical MBCs and immunity to malaria, but it 
demonstrates that the accumulation of atypical MBCs in 
the peripheral blood during and after malaria is associ-
ated with measures of clinical immunity. This association 
did not appear to merely be an artifact of age, since all 
participants in this study were nearly the same age, or of 
varied P. falciparum exposure, as results were unchanged 
in a multivariate analysis including estimates of expo-
sure. One possibility is that the ability to sustain asymp-
tomatic infections, which tend to be of longer duration 
than treated symptomatic malaria infections, leads to 
higher proportions of atypical MBCs due to chronic anti-
gen exposure. Alternatively, it may be that higher para-
site densities seen in less immune individuals drive down 
the proportion of atypical MBCs, possibly as a result of 
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Fig. 3 Fold change in atypical MBC and PC proportions from day 
14 to day 28 in participants who did and did not have a recurrent 
malaria episode between days 14 and 28 of follow‑up. a Fold changes 
in atypical MBC proportions. Participants with a second malaria 
episode had a significant increase in atypical MBC proportions from 
day 14 to when they presented with a recurrent malaria episode 
when tested by Wilcoxin signed‑rank test, but this increase was not 
significantly higher than the fold changes in participants who did 
not have a recurrent malaria episode. b Fold changes in PC propor‑
tions. Participants with a recurrent malaria episode had a significant 
increase in PC proportions from day 14 to when they presented with 
the recurrent malaria episode by Wilcoxin signed‑rank test. Addition‑
ally, this increase was significantly higher than the changes in partici‑
pants who did not have a recurrent malaria episode, as assessed by 
Wilcoxin rank sum test and indicated by asterisk above solid bar
(See figure on next page.) 
Fig. 4 Kinetics of atypical MBC, transitional and classical MBC proportions in participants categorized by parasite density and recent asymptomatic 
parasitaemia. a and b: participants were separated by day 0 parasite densities of greater than or less than 23,080 parasite/µl (green boxes, a), or by 
having at least one recently documented case of asymptomatic parasitaemia (purple boxes, b). c Lines were based on categories of parasite density 
from (a), and depict proportions of B cell sub‑sets over the 28‑day observation period following malaria (day 0). d Lines were based on category of 
asymptomatic parasitaemia from (b), and depict proportions of B cell sub‑sets over the 28‑day observation period following malaria (day 0). c and 
d Lines represent mean proportion for each group, with bars denoting 95 % confidence intervals. Asterisk, double asterisk and triple asterisk indicate 
a significant difference between groups at that timepoint as assessed by Wilcoxon rank sum test (p < 0.05, 0.01 and 0.001, respectively, ns = no 
significant difference)
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apoptosis or homing of atypical MBCs to tissues. It is 
also possible that atypical MBCs contribute, in an as-yet 
undefined manner, to anti-malarial immunity. Further 
studies are necessary to determine if atypical MBCs are 
causally associated with immunity to malaria.
Increases in transitional B cell proportions follow-
ing malaria have been previously noted, and this expan-
sion was hypothesized to be due to disruption of B cell 
homeostasis [19]. This study replicates the finding of 
increased proportions of circulating transitional B cell 
following malaria. In addition, this study found partici-
pants with greater parasite density at the time of malaria 
had higher proportions of transitional B cells. It is pos-
sible that this association could be driven by greater P. 
falciparum induced, non-specific, polyclonal B cell acti-
vation [39] and apoptosis [40] in individuals with higher 
parasite burdens, leading to a homeostatic expansion of 
transitional B cells. It is also possible that transitional B 
cells function in an immunoregulatory capacity [41], sim-
ilar to IL-10 producing T cells, in the context of malaria 
[42]. Transitional B cells from healthy US adults have 
been shown to secrete IL-10, a potent immunoregula-
tory cytokine, following CpG stimulation, and regulate 
T cell responses in vitro through IL-10 secretion [41, 43, 
44]. Further studies would be necessary in order to deter-
mine whether higher proportions of transitional B cells 
causally interfere with immunity to malaria, are a result 
of inadequate immune control of parasites, or whether 
expansion of this sub-set is associated with increased 
parasite densities for other reasons.
Outside of vaccine trials, plasmablasts/plasma cells 
can be difficult to characterize due to their paucity in 
the peripheral blood and highly synchronous migration 
to the bone marrow. Development and migration of PCs 
has been characterized in experimental infection of mice 
with P. chabaudi [9, 45, 46], but is not well described in 
humans. Although difficult to assess, these cells provide a 
snapshot of effector B cell responses formed in response 
to recent exposure. This study demonstrates that the day 
a person presents with symptomatic malaria may be an 
optimum time to characterize plasmablasts/plasma cells 
in peripheral blood. Given the findings, it may be pos-
sible in future studies to assess responding plasmablasts 
formed in response to acute infection and provide insight 
into emerging B cell responses to natural infection.
Some unique strengths of this study are the detailed 
longitudinal follow up of participants, allowing charac-
terization of relevant clinical outcomes and the meas-
urement of numerous B cell sub-type proportions at 
multiple timepoints during and following an episode of 
symptomatic malaria. By evaluating proportions of these 
sub-types at the time of malaria and following treatment, 
the potential confounding effects of the duration of time 
since malaria, which can affect the proportions of dif-
ferent cell types, was limited. Similarly, by evaluating 
children in a very narrow age range, the potential con-
founding effect of age, which is associated with immu-
nity to malaria and proportions of B cell sub-types, was 
reduced [11, 13]. The extensive longitudinal data avail-
able on study participants allowed the evaluation and 
adjustment for the individual’s varied exposure to P. fal-
ciparum, an important consideration when evaluating 
immunity.
A limitation of this study is the inability to determine 
whether associations between clinical phenotypes and 
proportions of B cell sub-sets represent a direct effect 
of these cell types. In addition, evaluation was lim-
ited to B cell sub-sets trafficking through peripheral 
blood which, while clearly an important compartment 
for interaction with a blood stage pathogen, may not 
represent proportions in other important compart-
ments such as secondary lymphoid organs or periph-
eral tissues. There is evidence using experimental 
mouse infection with P. chabaudi that memory B cell 
responses circulating in the blood reflected the gen-
eral composition of B cells in peripheral tissues [26]. 
Since peripheral lymphoid tissues are not easily sam-
pled, understanding circulating responses may pro-
vide the closest accessible insights to general B cell 
responses and homeostasis in humans. Another caveat 
to this study is that increased or decreased B cell sub-
set proportions could be a result of perturbations in 
another B cell sub-set, e.g., observed decreases in cir-
culating naïve B cell proportions could be the result of 
increases in transitional cell proportions. Consistent 
Table 2 Associations between  measures of  clinical immu-
nity and proportions of B cell sub-sets
Associations were measured using all sampling time points from each 
participant compared to either day 0 parasite densities or prior episodes 
of asymptomatic parasitaemia in previous 180 days. Day 0 parasite density 
≤ 23,080 parasites/μl n = 20 and > 23,080 parasites/μl n = 18. Of the 38 
participants in this study, ten had one or more episodes of asymptomatic 
parasitaemia in the previous 180 days
Results in italics have a significant analysis adjusted p value
a Median parasite density = 23,080 parasites/μl
b Linear relationship between 0, one and more than one episode
c Analysis adjusted for P. falciparum exposure, as estimated by the incidence of 
malaria in that child between 12 and 24 months of age
B cell sub‑set Day 0 parasite density 
<mediana
Mean difference in  % 
proportion (p value)
Asymptomatic parasi‑
taemia prior 180 daysb
Mean difference in  % 
proportion (p value)
Unadjusted Adjustedc Unadjusted Adjustedc
Atypical MBCs 4.5 (0.001) 5.1 (<0.001) 1.9 (0.05) 3.8 (0.04)
Transitional −2.6 (0.08) −3.6 (0.02) −0.6 (0.5) −1.1 (0.3)
Classical MBCs −0.2 (0.8) 0.4 (0.7) −0.6 (0.3) −0.2 (0.7)
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with methods from several earlier prior studies [11, 
13, 14, 22, 47], the design of this study only allowed for 
measurement of relative proportions and not absolute 
B cell counts; future studies may want to account for 
changes in absolute numbers of cells as well as propor-
tions. Additional studies focusing on the mechanisms 
of action of atypical MBCs and transitional B cells are 
also needed to provide insight into the causal relation-
ships underlying the associations observed.
Conclusions
The findings of this study highlight the importance of 
investigating the dynamics of multiple B cell sub-sets, 
including consideration of the timing of these measure-
ments with respect to malaria, in order to understand the 
contribution of the humoral immune system in devel-
oping immunity to malaria. Infection by P. falciparum 
greatly affects B cell homeostasis, but further research 
is necessary to understand the full implications of these 
changes. Since most vaccines are designed to induce 
a protective B cell response that can be sustained over 
time, it is vital to understand consequences of P. falcipa-
rum infection on the humoral immune system, memory 
formation and maintenance of memory.
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